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Abstract
Background: Decreased expression of the angiogenesis inhibitor ADAMTS1 (ADAM metallopeptidase with 
thrombospondin type 1 motif, 1) has previously been reported during prostate cancer progression. The aim of this 
study was to investigate the function of ADAMTS1 in prostate tumors.
Methods: ADAMTS1 was downregulated by shRNA technology in the human prostate cancer cell line LNCaP 
(androgen-dependent), originally expressing ADAMTS1, and was upregulated by transfection in its subline LNCaP-19 
(androgen-independent), expressing low levels of ADAMTS1. Cells were implanted subcutaneously in nude mice and 
tumor growth, microvessel density (MVD), blood vessel morphology, pericyte coverage and thrombospondin 1 (TSP1) 
were studied in the tumor xenografts.
Results: Modified expression of ADAMTS1 resulted in altered blood vessel morphology in the tumors. Low expression 
levels of ADAMTS1 were associated with small diameter blood vessels both in LNCaP and LNCaP-19 tumors, while high 
levels of ADAMTS1 were associated with larger vessels. In addition, TSP1 levels in the tumor xenografts were inversely 
related to ADAMTS1 expression. MVD and pericyte coverage were not affected. Moreover, upregulation of ADAMTS1 
inhibited tumor growth of LNCaP-19, as evidenced by delayed tumor establishment. In contrast, downregulation of 
ADAMTS1 in LNCaP resulted in reduced tumor growth rate.
Conclusions: The present study demonstrates that ADAMTS1 is an important regulatory factor of angiogenesis and 
tumor growth in prostate tumors, where modified ADAMTS1 expression resulted in markedly changed blood vessel 
morphology, possibly related to altered TSP1 levels.
Background
Extracellular matrix (ECM) proteases are involved in sev-
eral steps of cancer development and progression, includ-
ing angiogenesis and metastasis. By cleavage of ECM
components, proteases regulate endothelial cell migra-
tion and the selective release and modulation of pro- and
anti-angiogenic factors [1].
ADAMTS1 (ADAM metallopeptidase with thrombos-
pondin type 1 motif, 1) is a widely expressed matrix met-
alloproteinase with documented roles in angiogenesis
and tumor biology [2-6]. It has been described as a potent
anti-angiogenic factor that effectively inhibits endothelial
cell proliferation and angiogenesis in experimental assays
[2]. As the name indicates, the ADAMTS1 protein com-
prises a metalloproteinase domain and three thrombos-
pondin (TSP) type I motifs [7], both of which is
important for the angioinhibitory capacity. The TSP type
I motifs of ADAMTS1 have been reported to directly
bind vascular endothelial growth factor (VEGF)165, and
thereby block its angiogenic function [8]. In addition, the
metalloproteinase domain has the ability to release anti-
angiogenic fragments through cleavage of matrix-bound
TSP1 and -2 [9]. TSP1 is one of the most studied endoge-
nous inhibitor of angiogenesis, and downregulation of
TSP1 is common in a variety of tumor types, including
prostate cancer [10].
ADAMTS1 has been reported to efficiently inhibit
tumor growth and metastasis in different experimental
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cancer models by blocking angiogenesis [3-5], and
decreased expression of ADAMTS1 has been reported in
human malignancies [11-13]. However, the involvement
of ADAMTS1 in tumor progression is complex, with data
also describing ADAMTS1 as a tumor promoting factor
[4-6]. The tumor promoting effect is believed to involve
the release of growth factors from ECM, and there are
studies suggesting that the proteolytic status of
ADAMTS1 is of importance for its effect on tumor
growth [4,5].
In human prostate cancer, angiogenesis is related to
clinical stage, progression, metastasis and survival [14-
18]. In addition, androgen-independent or castration
resistant prostate cancer (i.e. tumors relapsing from
androgen deprivation therapy) displays higher MVD
compared to androgen-dependent tumors [19-21]. Thus,
factors affecting regulation of blood vessels and angio-
genesis are of importance for the progression of prostate
cancer, and may also be candidate targets for anti-angio-
genic treatment. In a previous study, we identified
ADAMTS1 as a gene that was downregulated when the
androgen-dependent human prostate cancer cell line
LNCaP progressed into an androgen-independent sub-
line, LNCaP-19 [22]. This transition into androgen-inde-
pendency was also associated with enhanced malignancy,
increased MVD, altered blood vessel morphology and
less pericyte covered vessels [23-25]. Furthermore,
decreased expression of ADAMTS1 was found in tumor
tissue from prostate cancer patients compared to benign
prostate tissue, and low levels of ADAMTS1 were associ-
ated with increased MVD and metastasis in androgen-
independent tumors [19].
This study was conducted to investigate the actual
function of ADAMTS1 in prostate cancer. ADAMTS1
expression was downregulated in LNCaP cells (andro-
gen-dependent) with shRNA technology and was upregu-
lated in LNCaP-19 (androgen-independent) by
transfection with an expression vector containing full-
length ADAMTS1. We report that modified expression of
ADAMTS1 resulted in markedly changed blood vessel
morphology and TSP1 levels in the tumor xenografts,
while MVD and pericyte coverage was unaffected. More-
over, the effect of ADAMTS1 on tumor growth was dif-
ferent in LNCaP and LNCaP-19. The results from this
study demonstrate that ADAMTS1 is an important regu-
latory factor of angiogenesis and tumor growth in pros-
tate tumors.
Methods
Cell lines and cell culture
The androgen-dependent human prostate cancer cell line
LNCaP was obtained from American Type Culture Col-
lection (ATCC, Manassas, VA). The androgen-indepen-
dent cell line LNCaP-19 was previously established from
LNCaP in our laboratory and cells were maintained as
previously described [23].
Expression vectors and transfection of cells
SureSilencing shRNA plasmids for human ADAMTS1
with neomycin (#KH01149N, SABiosciences, Frederick,
M D )  w e r e  u s e d  t o  d o w n r e g u l a t e  t h e  e x p r e s s i o n  o f
ADAMTS1 by RNA interference in LNCaP cells. A plas-
mid expressing shRNA that does not match any human,
mouse or rat gene was included as control. LNCaP -19
cells were transfected with a mammalian expression vec-
tor containing the full-length wild-type mouse
ADAMTS1 [4] or empty control vector (pcDNA3). Cells
were transfected over night with 8 μg DNA and 20 μl
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in 6 ml
culture medium without antibiotics. Three days after
transfection, cells were subjected to selective pressure by
adding Geneticin (400 μg/ml, Invitrogen). Three weeks
later, stably transfected clones were isolated, expanded
and screened for ADAMTS1 expression by real-time RT-
PCR and western blotting. Several clones were obtained
and one clone from each group was selected for in vivo
studies.
Animal experiments
Isolated clones and wild-type cells were implanted subcu-
taneously in male athymic BALB/c nude mice, 8-10
weeks old (Charles River Laboratories, Wilmington,
MA). The use of animals was approved by the animal eth-
ical committee in Gothenburg (Nr: 228-2006). Two mil-
lion cells, diluted in 100 μl culture medium and 100 μl
Matrigel (BD Biosciences, Bedford, MA), were injected
subcutaneously in the flank of the mice. To represent the
clinical situation, LNCaP cells (wild-type = L wt, control
transfected = LC and ADAMTS1 shRNA-transfected =
LA-) were implanted in intact mice, while LNCaP-19 cells
(wild-type = L19 wt, control transfected = L19C and
ADAMTS1 transfected = L19A+) were implanted in cas-
trated mice. Each clone was implanted in eight mice.
Mice used for implantation of LNCaP-19 clones were
castrated under anesthesia three days before inoculation.
In a separate control experiment L19C and L19A + were
also implanted in intact mice. Tumors were measured
with a caliper and tumor volumes were calculated using
the formula; (length × width2)/2. When tumor size
reached about 1.3 cm3, or after a maximum of 15 weeks,
m i c e  w e r e  s a c r i f i c e d  a n d  t u m o r s  w e r e  r e m o v e d  a n d
weighed. Tumor take rate was defined as percentage of
animals with a palpable tumor at different time points
after implantation. Tumor growth rate was calculated as
tumor weight (mg) divided with the number of days from
implantation to sacrifice, and then related to the growth
rate of wt tumors. One part of the tumors was fixed inGustavsson et al. BMC Cancer 2010, 10:288
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formalin for paraffin embedding and one part was frozen
in liquid nitrogen and stored in -80°C.
RNA preparation and real-time RT-PCR
Total RNA from cells and tumor tissue was isolated with
the RNeasy Plus Mini kit and treated with RNase-free
DNase I (Qiagen, Hilden, Germany) according to the
manufacturer's protocol. RNA concentration and purity
were determined spectrophotometrically, and the integ-
rity of RNA was confirmed by gel electrophoresis.
Reverse transcription of total RNA was performed as pre-
viously described [22]. Real-time RT-PCR was performed
with TaqMan Gene Expression Assays in a 7500 Fast
Real-Time PCR System (Applied Biosystems, Foster City,
CA), according to the manufacturer's protocol. The Taq-
Man Gene Expression Assays used were; human
ADAMTS1 (Hs00199608_m1), mouse Adamts1
(Mm00477355_m1) and 18S (Hs99999901_s1). The real-
time RT-PCR analysis was performed in duplicates and
was repeated twice. Data were analyzed according to the
ΔΔCt method for relative quantification according to
Applied Biosystems' instructions and were normalized to
the expression of 18S rRNA.
Protein preparation and Western blotting
Protein extraction and western blotting was performed as
previously described [22]. Primary antibodies used were
against; human ADAMTS1 (1:500, #A4476, Sigma-
Aldrich, St Louis, MO), mouse ADAMTS1 (1:5000,
k i n d l y  p r o vi d ed  b y  P r o f .  J o a n n e  S.  R i c h a r ds  [ 2 6 ] ) ,  a n d
TSP1 (1:400, #MS-421-P1, NeoMarkers, Fremont, CA).
The TSP-1 antibody reacts with the C-terminal of the
protein and has earlier been reported to detect full-length
TSP1 and ADAMTS1 cleaved TSP1 [9]. As loading con-
trol an antibody against actin (1:500, #A2066, Sigma-
Aldrich) was used. Chemiluminescent signals were visu-
alized by the LAS-4000 CCD camera (Fujifilm, Tokyo,
Japan) and semi-quantitative analysis of immunoreactive
bands was performed with the free computer software
ImageJ http://rsb.info.nih.gov/ij/.
Cell proliferation assay
Cells were seeded in triplicates in 96-well plates at a den-
sity of 5000 cells/well in regular culture medium. Cells
were incubated for four days and then frozen at -80°C.
Proliferation was analyzed using the CyQUANT Cell Pro-
liferation Assay Kit (Invitrogen) according to the manu-
facturer's protocol. A fluorescent dye that binds to DNA
was added and fluorescence was measured with a Victor3
multilabel plate reader (PerkinElmer, Waltham, MA).
Proliferation experiments were repeated twice.
Detection of blood vessels in tumors
M V D ,  b l o o d  v e s s e l  m o r p h o l o g y  a n d  p e r i cy t e  c o v e r a g e
were analyzed by immunohistochemistry. For determina-
tion of MVD and blood vessel morphology, sections were
stained with an antibody against CD34 (1:20, #ab8158,
Abcam, Cambridge, UK). To analyze pericyte coverage,
another set of sections were double stained with the
CD34 antibody and an antibody against α-SMA (1:20,
#A5691, Sigma-Aldrich). Immunohistochemistry was
performed as previously described [22,25]. MVD was
evaluated by counting the number of CD34-positive ves-
sels in five objective fields of representative areas in each
section. Blood vessel morphology was assessed by group-
ing the tumors into two groups according to the form and
distribution of vessels. Tumors characterized by large,
thick and singly distributed vessels, often with a visible
lumen were denoted as LV (large vessels), while tumors
characterized by small and thin vessels forming networks
without a visible lumen were assigned as SV (small ves-
sels). The evaluation was based on the total area of the
section and included both peripheral and central parts of
the tumor. To evaluate pericyte coverage index, all CD34-
positive vessels associated with α-SMA positive cells were
counted and divided with the total number of CD34-pos-
itive vessels in five objective fields in each section. All
analyses were performed independently by two investiga-
tors at 200 × magnification.
Statistical analyses
Data are presented as mean ± SEM. Mann Whitney U
test was used to compare differences between groups.
Fisher's exact test was used to compare the tumor take
rate between groups. A P-value < 0.05 was considered
statistically significant. All statistical analyses were per-
formed using SPSS 16.0 software for Windows.
Results
Modified expression of ADAMTS1 in LNCaP and LNCaP-19 
cells
LNCaP cells (L wt) that originally express significant
amounts of ADAMTS1 were stably transfected with
shRNA plasmids against ADAMTS1 (LA-) or control
vector (LC). LNCaP-19 cells (L19 wt), originally express-
ing low amounts of ADAMTS1, were stably transfected
with an expression vector containing the full-length
ADAMTS1 (L19A+) or control vector (L19C). To repre-
sent the clinical situation LNCaP cells were inoculated in
intact mice, while LNCaP-19 cells were implanted in cas-
trated mice. Real-time RT-PCR and western blotting
analysis revealed significantly decreased mRNA and pro-
tein levels of ADAMTS1 in LA- tumors compared to LC
tumors (Figure 1A, B, C) and an obvious increase in
ADAMTS1 expression in L19A + tumors compared to
L19C tumors (Figure 1D, E, F). Both the latent form (110
kDa) and the active form (87 kDa) of ADAMTS1 protein
that are present in LNCaP were also present in L19A +
tumors.Gustavsson et al. BMC Cancer 2010, 10:288
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Tumor growth of LNCaP and LNCaP-19 was differently 
affected by ADAMTS1
Decreased levels of ADAMTS1 did not affect tumor take
of androgen-dependent LNCaP cells (Figure 2A), but
strongly inhibited tumor growth rate. Tumor growth rate,
measured as tumor weight/days in relation to LNCaP wt,
was reduced with approximately 80% from 1.05 (±0.16) in
LC tumors to 0.20 (±0.07) in LA- tumors (P < 0.01) (Fig-
ure 2B). Measurements of tumor volumes displayed simi-
lar results (Figure 2C). However, the proliferation rate in
vitro was not affected (Figure 2D). In contrast, increased
levels of ADAMTS1 in LNCaP-19 resulted in markedly
slower tumor establishment. All mice in the L19C group
had palpable tumors already after one week, while tumors
in the L19A + group gradually became palpable during 9
weeks (Figure 3A). The relative tumor growth rate was
1.03 (±0.23) in L19C tumors and 0.66 (±0.18) in L19A +
tumors (P  = 0.279) (Figure 3B). Similar results were
obtained when measuring tumor volumes (Figure 3C).
However, there was no statistically significant effect on
tumor growth rate once tumors were established. No dif-
ference in proliferation rate was observed in vitro (Figure
3D).
The discrepancy in tumor growth regulation between
LNCaP and LNCaP-19 was not due to the fact that
LNCaP-19 tumors were growing in castrated mice, while
LNCaP tumors were growing in intact mice, since similar
results were obtained when L19C and L19A + cells were
implanted in intact mice as control (Figure 3B).
ADAMTS1 altered tumor blood vessel morphology but not 
MVD or pericyte coverage
Modified expression of ADAMTS1 induced a clear differ-
ence in blood vessel morphology. In LNCaP tumors,
blood vessels in the L wt and LC groups were observed as
singly distributed vessels that were larger, thicker and
rounder in shape often with a visible lumen (assigned as
LV = large vessels). In contrast, when ADAMTS1 was
downregulated (LA-), the tumors were dominated by
small and thin vessels forming long networks, mainly
without a visible lumen (assigned as SV = small vessels).
The blood vessel morphology was similarly affected by
Figure 1 Expression of ADAMTS1 in tumor xenografts. (A, D) mRNA expression of ADAMTS1 in tumor xenografts was analyzed by real-time RT-
PCR, normalized to the expression of 18S rRNA and presented as relative expression compared to wild-type tumors. (B, E) Protein levels of ADAMTS1 
in tumor xenografts were analyzed by western blotting. ADAMTS1 was detected in its latent form (110 kDa, arrows) as well as in its active form (87 
kDa, arrowheads) and actin was used as loading control. Western blotting membranes showing one representative sample from each group. (C, F) 
Densitometric analysis presented as relative levels of active ADAMTS1 (87 kDa) to actin. Results are presented as mean ± SEM. Mann Whitney U test 
was used to compare differences between groups, ** = P < 0.01. (A-C) LNCaP wild-type (L wt, n = 8), control transfected LNCaP (LC, n = 8) and 
ADAMTS1 shRNA-transfected LNCaP (LA-, n = 6). (D-F) LNCaP-19 wild-type (L19 wt, n = 6), control transfected LNCaP-19 (L19C, n = 8) and ADAMTS1 
transfected LNCaP-19 (L19A+, n = 6).
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ADAMTS1 expression in LNCaP-19 tumors. The tumors
with low ADAMTS1 (L19 wt and L19C) were dominated
by smaller and thinner vessel networks (SV), while L19A
+ tumors displayed singly distributed blood vessels that
were rounder and thicker in shape (LV) (Figure 4). How-
ever, ADAMTS1 did not affect MVD (Figure 5A, C) or
the proportion of α-SMA positive vessels, representing
pericyte covered vessels (Figure 5B, D), neither in LNCaP
nor in LNCaP-19 tumors.
ADAMTS1 affected the TSP1 levels in tumors
Since ADAMTS1 has been reported to cleave TSP1, we
analyzed the protein forms of TSP1 by western blotting.
TSP1 was detected as two immunoreactive bands of
approximately the same size that previously was
described as full-length TSP1 (145 kDa) and ADAMTS1
cleaved TSP1 (110 kDa) [9]. However, modified expres-
sion of ADAMTS1 did not alter the ratio between the two
detected protein forms either in LNCaP or LNCaP-19
tumors. Instead, the total protein levels of detected TSP1
Figure 2 Growth of LNCaP clones in vivo and in vitro. LNCaP cells were implanted subcutaneously in nude mice and the experiment was ended 
when tumor size reached about 1.3 cm3, or after a maximum of 15 weeks. LNCaP wild-type (L wt, n = 8), control transfected LNCaP (LC, n = 8) and 
ADAMTS1 shRNA-transfected LNCaP (LA-, n = 7). (A) Tumor take rate is presented as percentage of animals with a palpable tumor at different time 
points after implantation. Fisher's exact test was used to compare the tumor take rate between groups. (B) Tumor growth rate was calculated as tumor 
weight (mg) divided with the number of days from implantation to sacrifice and presented as the relative growth rate compared to wild-type tumors. 
Results are presented as mean ± SEM. Mann Whitney U test was used to compare differences between groups, ** = P < 0.01. (C) Tumor volumes were 
calculated as (length × width2)/2. (D) Proliferation rate in vitro of LC and LA- in relation to L wt. Cells were seeded in 96-well plates in their regular cell 
culture medium. Four days later, DNA was quantified by a fluorescent dye and values were related to the wild-type cells. Mean ± SEM of two indepen-
dent experiments with triplicates are shown.
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were markedly affected by ADAMTS1 levels. TSP1 was
present in L19 wt, but not in L wt. Downregulation of
ADAMTS1 in LNCaP resulted in increased levels of
TSP1 (Figure 6A, B), and upregulation of ADAMTS1 in
LNCaP-19 was associated with decreased levels of TSP1
(Figure 6C, D).
Discussion
In the present study, we modified the expression of
ADAMTS1 in an experimental model of prostate cancer
to investigate the function of this protein. The main find-
ings were that ADAMTS1 altered the blood vessel mor-
phology and TSP1 levels in the tumor xenografts. In
addition, the tumor growth was differently affected by
ADAMTS1 in androgen-dependent LNCaP and andro-
gen-independent LNCaP-19 tumors.
In prostate cancer, an increased angiogenesis is
observed in androgen-independent and metastatic dis-
ease and this is probably important for the rapid growth
and spreading of the cancer [17,19,23]. Since ADAMTS1
is known as a potent inhibitor of angiogenesis in other
systems and previously has been reported to decrease
during prostate cancer progression, we investigated its
effects on tumor blood vessels. Interestingly, we found
Figure 3 Growth of LNCaP-19 clones in vivo and in vitro. LNCaP-19 cells were implanted subcutaneously in nude mice and the experiment was 
ended when tumor size reached about 1.3 cm3, or after a maximum of 15 weeks. LNCaP-19 wild-type (L19 wt, n = 6), control transfected LNCaP-19 
(L19C, n = 8) and ADAMTS1 transfected LNCaP-19 (L19A+, n = 8) (A) Tumor take rate is presented as percentage of animals with a palpable tumor at 
different time points after implantation. Fisher's exact test was used to compare the tumor take rate between groups, ** = P < 0.01, * = P < 0.05 L19A+ 
vs. L19C. (B) Tumor growth rate of L19C and L19A+ in castrated as well as in intact mice (intact mice; L19C, n = 8 and L19A+, n = 7) was calculated as 
tumor weight (mg) divided with the number of days from implantation to sacrifice and presented as the relative growth rate compared to wild-type 
tumors. Results are presented as mean ± SEM. Mann Whitney U test was used to compare differences between groups. (C) Tumor volumes were cal-
culated as (length × width2)/2. (D) Proliferation rate in vitro of L19C and L19A+ in relation to L19 wt. Cells were seeded in 96-well plates in their regular 
cell culture medium. Four days later, DNA was quantified by a fluorescent dye and values were related to the wild-type cells. Mean ± SEM of two in-
dependent experiments with triplicates are shown.
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that modified expression of ADAMTS1 markedly altered
the blood vessel morphology in these tumor xenografts,
while the number of blood vessels was unaffected. During
the transition of LNCaP into LNCaP-19, an altered blood
vessel morphology was observed together with increased
MVD and the loss of ADAMTS1 [22,23]. In this study,
downregulation of ADAMTS1 in LNCaP resulted in a
blood vessel phenotype characteristic of LNCaP-19
tumors with small diameter vessels forming long net-
works. By upregulation of ADAMTS1 in LNCaP-19, the
vessel morphology could be reversed into a phenotype
resembling the blood vessels in LNCaP tumors, charac-
terized by larger vessels. These results demonstrate that
ADAMTS1 is a regulator of blood vessel biology also in
prostate tumors. The significance of this switch in blood
vessel morphology for tumor progression is not exten-
sively investigated. However, it was recently shown in a
large prospective study of prostate cancer patients that
the vessel morphology is of importance for the clinical
outcome. It was shown that small blood vessels were
associated with poorly differentiated tumors. More inter-
estingly, men whose tumors had a small vessel diameter
or a small vessel area were about 6 times more likely to
develop lethal prostate cancer, even after adjustment for
age, differentiation (Gleason score) and PSA [27]. This
new data together with our results presented here,
implies that loss of ADAMTS1 could be an important
mediator of the progression into more aggressive prostate
cancer.
ADAMTS1 has previously been reported to regulate
angiogenesis by cleaving TSP1, which results in the
release of TSP1 from ECM and thereby to decreased
angiogenesis [9]. However, modified ADAMTS1 expres-
sion did not affect the cleavage of TSP1 in LNCaP or
LNCaP-19 tumors. Instead, we found that ADAMTS1
expression was inversely related to the total levels of
TSP1 in the tumor xenografts. Since TSP1 is a potent
angiogenesis inhibitor, this may explain why the MVD in
the tumor xenografts was not affected by altered levels of
ADAMTS1. Interestingly, TSP1 has also been described
to affect blood vessel morphology. Mammary tumors in
TSP1-null mice have been reported to display signifi-
Figure 4 Blood vessel morphology in tumor xenografts. Blood vessels were stained for CD34 and morphology was evaluated in light microscopy 
at 200 × magnification. Tumors characterized by large and thick, singly distributed vessels, often with a visible lumen were assigned as LV = large ves-
sels, while tumors characterized by small and thin vessels forming networks without a visible lumen were assigned as SV = small vessels. (A) Images 
showing the blood vessel morphology in typical LV and SV tumors in LNCaP and LNCaP-19 tumors with modified ADAMTS1. (B) Tumors were classified 
unaware of origin into LV or SV. Histograms show the distribution of tumors between LV and SV in LNCaP tumors (upper panel); control transfected 
LNCaP (LC, n = 8) and shRNA transfected LNCaP (LA-, n = 6) and in LNCaP-19 tumors (lower panel); control transfected LNCaP-19 (L19C, n = 8) and 
ADAMTS1 transfected LNCaP-19 (L19A+, n = 7).
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cantly larger blood vessels than tumors in wild-type mice
[28,29]. This is in accordance with our study, where
decreased expression of ADAMTS1 was associated with
increased TSP1 and a switch from large vessels into small
vessels, while overexpression of ADAMTS1 resulted in
loss of TSP1 and a switch back to larger vessels. Thus, the
A D AM T S 1 - m e d i a t e d  e f f e c t  o n  T S P 1  l ev e l s  c o u l d  be  a
possible mechanism responsible for the switch in blood
vessel morphology observed.
Tumor blood vessels are often characterized by
decreased pericyte coverage, making them less stabilized,
more permeable and more sensitive to angiogenic stimuli
[30]. LNCaP tumors have previously been described to
have more vessels stabilized by pericytes than LNCaP-19
t u m o r s  [ 2 5 ] .  H o w e v e r ,  m o d i f i e d  e x p r e s s i o n  o f
ADAMTS1 did not influence the degree of pericyte cov-
erage, indicating that altered vessel stabilization by peri-
cytes is not involved in the altered blood vessel
morphology observed.
ADAMTS1 is a multifunctional protein reported to
have both pro- and anti-tumorigenic properties. Transi-
tion of the cell line LNCaP into its more malignant sub-
line LNCaP-19 has previously been reported to result in
l o s s  o f  A D A M T S 1  t o g e t h e r  w i t h  a  m o r e  r a p i d  t u m o r
establishment [22,23]. Also in the human prostate,
ADAMTS1 was downregulated in tumor tissue com-
pared to benign tissue and decreased expression of
ADAMTS1 was associated with increased angiogenesis
and metastasis in androgen-independent tumors [19]. In
this study, re-expression of ADAMTS1 in LNCaP-19
greatly delayed tumor establishment, indicating that
ADAMTS1 actually might function as a tumor suppres-
sor of androgen-independent prostate tumors. However,
once tumors were established the LNCaP-19 cells seem
to escape from this inhibitory effect of ADAMTS1, since
no obvious difference in tumor growth rate was observed.
That increased expression of ADAMTS1 is associated
with a less malignant phenotype of androgen-indepen-
d e n t  p r o s t a t e  t u m o r s  h a s  a l s o  b e e n  s h o w n  i n  P C - 3
tumors [31]. However, downregulation of ADAMTS1 in
LNCaP resulted in a reduced tumor growth rate, suggest-
ing that ADAMTS1 rather is a tumor promoting factor in
androgen-dependent LNCaP tumors. Other experimen-
tal studies also report conflicting data regarding
ADAMTS1 as a pro- or anti-tumorigenic factor, and the
proteolytic status of ADAMTS1 has been proposed to be
of importance for its effect [4,5]. However, in this study
Figure 5 Microvessel density and pericyte covered blood vessels 
in tumor xenografts. (A, C) Microvessel density. Blood vessels were 
stained for CD34 and the number of vessels was counted in five fields 
of each tumor in light microscopy at 200 × magnification. Results are 
presented as mean number of vessels per field ± SEM. (B, D) Percent-
age of pericyte covered blood vessels. Blood vessels were double 
stained for CD34 and α-SMA. The number of α-SMA positive blood ves-
sels were counted and divided with the total number of CD34 positive 
vessels in five fields of each tumor at 200 × magnification. Results are 
presented as mean ± SEM. (A-B) Control transfected LNCaP (LC, n = 8) 
and shRNA-transfected LNCaP (LA-, n = 6). (C-D) Control transfected 
LNCaP-19 (L19C, n = 8) and ADAMTS1 transfected LNCaP-19 (L19A+, n 
= 7).
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Figure 6 TSP1 levels in tumor xenografts. (A, C) TSP1 levels in tu-
mor xenografts were analyzed by western blotting. TSP1 was detected 
in its full-length form (145 kDa, arrows) as well as in a smaller cleaved 
form (110 kDa, arrowheads). Actin was used as loading control. West-
ern blotting membranes showing one representative sample from 
each group. (B, D) Densitometric analysis presented as relative levels of 
TSP1 to actin. Results are presented as mean ± SEM. Mann Whitney U 
test was used to compare differences between groups, * = P < 0.05. (A-
B) LNCaP tumors from LNCaP wild-type (L wt, n = 8), control transfect-
ed cells (LC, n = 8) and ADAMTS1 shRNA-transfected cells (LA-, n = 6). 
(C-D) LNCaP-19 tumors from LNCaP-19 wild-type (L19 wt, n = 6), con-
trol transfected cells (L19C, n = 8) and ADAMTS1 transfected cells 
(L19A+, n = 6).
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ADAMTS1 was only detected in its latent and full-length
active form in both LNCaP and LNCaP-19 tumors, sug-
gesting that this is not the reason to the difference in
tumor growth regulation in this model. Since ADAMTS1
is a multifunctional protein mainly acting indirectly on
tumor cells by regulating the availability and activity of
factors present in the ECM, the constitution of the sur-
rounding ECM is probably of great importance for the
net effect of ADAMTS1.
Conclusions
In conclusion, modified ADAMTS1 expression resulted
in markedly changed blood vessel morphology and
altered TSP1 levels in the tumors. Loss of ADAMTS1 was
a s s o c i a t e d  w i t h  s m a l l  d i a m e t e r  v e s s e l s  t h a t  h a v e  b e e n
associated with more aggressive prostate tumors. Alto-
gether, the results presented in this paper further support
that ADAMTS1 is an important regulatory factor of
tumor growth and angiogenesis during prostate cancer
progression.
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